Drug retention rates and treatment discontinuation among anti-TNF- α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Fabbroni, Marta ^a   Cantarini, Luca ^a   Caso, Francesco ^a,b   Costa, Luisa ^c   Pagano, Veronica Anna ^d   Frediani, Bruno ^a   Manganelli, Stefania ^a   Galeazzi, Mauro ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d TFS Develop   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; DISEASE DURATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED CANCER; DRUG RETENTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; MUCOSAL DISEASE; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; DRUG ADMINISTRATION; MIDDLE AGED; SPONDYLITIS, ANKYLOSING;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904691284     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/862969     Document Type: Article

References (49)

1. Baraliakos X., Braun J., Spondyloarthritides. Best Practice and Research: Clinical Rheumatology 2011 25 6 825 842 2-s2.0-84856013195 10.1016/j.berh.2011. 11.006
2. Tillett W., Costa L., Jadon D., Wallis D., Cavill C., McHugh J., Korendowych E., McHugh N., The ClASsification for Psoriatic ARthritis (CASPAR) criteria-a retrospective feasibility, sensitivity, and specificity study. Journal of Rheumatology 2012 39 1 154 156 2-s2.0-84855384543 10.3899/jrheum.110845
3. Soscia E., Sirignano C., Catalano O., Atteno M., Costa L., Caso F., Peluso R., Bruner V., Aquino M. M., del Puente A., Salvatore M., Scarpa R., New developments in magnetic resonance imaging of the nail unit. Journal of Rheumatology 2012 39 89 49 53 2-s2.0-84864578000 10.3899/jrheum.120243
4. Costa L., Caso F., D'Elia L., Atteno M., Peluso R., Del Puente A., Strazzullo P., Scarpa R., Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clinical Rheumatology 2012 31 4 711 715 2-s2.0-84859781651 10.1007/s10067-011-1892-1
5. Schatteman L., Mielants H., Veys E. M., Cuvelier C., de Vos M., Gyselbrecht L., Elewaut D., Goemaere S., Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. Journal of Rheumatology 1995 22 4 680 683 2-s2.0-0028961892
6. del Puente A., Esposito A., Parisi A., Atteno M., Montalbano S., Vitiello M., Esposito C., Bertolini N., Foglia F., Costa L., Scarpa R., Osteoporosis and psoriatic arthritis. Journal of Rheumatology 2012 39 89 36 38 2-s2.0-84864409570 10.3899/jrheum.120240
7. Gupta N., Saigal R., Goyal L., Agrawal A., Bhargava R., Agrawal A., Carotid intima media thickness as a marker of atherosclerosis in ankylosing spondylitis. International Journal of Rheumatology 2014 2014 5 10.1155/2014/839135 839135
8. Perrotta F. M., Scarno A., Carboni A., Bernardo V., Montepaone M., Lubrano E., Spadaro A., Assessment of subclinical atherosclerosis in ankylosing spondylitis: correlations with disease activity indices. Reumatismo 2013 65 3 105 112 2-s2.0-84880649554 10.4081/reumatismo.2013.105
9. Resorlu H., Akbal A., Resorlu M., Gokmen F., Ates C., Uysal F., Adam G., Aylanc N., Arslan M., Inceer B. S., Epicardial adipose tissue thickness in patients with ankylosing spondylitis. Clinical Rheumatology 2014 10.1007/s10067-014-2568-4
10. Stolwijk C., van Tubergen A., Castillo-Ortiz J. D., Boonen A., Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Annals of the Rheumatic Diseases 2013 10.1136/annrheumdis-2013-203582
11. Hreggvidsdottir H. S., Noordenbos T., Baeten D. L., Inflammatory pathways in spondyloarthritis. Molecular Immunology 2014 57 28 37 2-s2.0-84881530257 10.1016/j.molimm.2013.07.016
12. Scarpa R., Costa L., AttenoM, Del Puente A., Caso F., Moll J. M., Psoriatic arthritis: advances in pharmacotherapy based on molecular target. Expert Opinion on Pharmacotherapy 2013 14 2311 2313
13. Fiocco U., Sfriso P., Oliviero F., Lunardi F., Calabrese F., Scagliori E., Cozzi L., di Maggio A., Nardacchione R., Molena B., Felicetti M., Gazzola K., Stramare R., Rubaltelli L., Accordi B., Costa L., Roux-Lombard P., Punzi L., Dayer J.-M., Blockade of intra-articular TNF in peripheral spondyloarthritis: Its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine 2013 80 2 165 170 2-s2.0-84875526503 10.1016/j.jbspin.2012.06.016
14. Sieper J., Developments in therapies for spondyloarthritis. Nature Reviews Rheumatology 2012 8 5 280 287 2-s2.0-84860572793 10.1038/nrrheum.2012.40
15. Fénix-Caballero S., Alegre-Del Rey E. J., Castaño-Lara R., Puigventõs-Latorre F., Borrero-Rubio J. M., Lõpez-Vallejo J. F., Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. Journal of Clinical Pharmacy and Therapeutics 2013 38 4 286 293 2-s2.0-84879994854 10.1111/jcpt.12045
16. Baraliakos X., van den berg R., Braun J., van der heijde D., Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology 2012 51 8 1378 1387 2-s2.0-84865172773 10.1093/rheumatology/kes026 kes026
17. Costa L., Caso F., Atteno M., del Puente A., Darda M. A., Caso P., Ortolan A., Fiocco U., Ramonda R., Punzi L., Scarpa R., Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clinical Rheumatology 2013 2-s2.0-84881508958 10.1007/s10067-013-2369-1
18. El Maghraoui A., Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. European Journal of Internal Medicine 2011 22 6 554 560 2-s2.0-80855131442 10.1016/j.ejim.2011.06.006
19. Atteno M., Costa L., Matarese A., Caso F., Del Puente A., Cantarini L., Bocchino M. L., Sanduzzi A., Scarpa R., The use of TNF- α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clinical Rheumatology 2014 33 543 547
20. Costa L., Caso F., Atteno M., Giannitti C., Spadaro A., Ramonda R., Vezzù M., del Puente A., Morisco F., Fiocco U., Galeazzi M., Punzi L., Scarpa R., Long-term safety of anti-TNF- α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clinical Rheumatology 2014 33 273 276 2-s2.0-84882309747 10.1007/s10067-013-2378-0
21. Sieper J., Developments in the scientific and clinical understanding of the spondyloarthritides. Arthritis Research and Therapy 2009 11 1, article 208 2-s2.0-60549114195 10.1186/ar2562
22. Davis J. C. Jr., Mease P. J., Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic. Seminars in Arthritis and Rheumatism 2008 38 2 83 100 2-s2.0-52149084828 10.1016/j.semarthrit.2007.10.007
23. Haroon N., Inman R. D., Learch T. J., The Impact of TNF-inhibitors on radiographic progression in Ankylosing Spondylitis. Arthritis and Rheumatism 2013 65 10 2645 2654 10.1002/art.38070
24. van der Heijde D., Landewé R., Einstein S., Ory P., Vosse D., Ni L., Lin S.-L., Tsuji W., Davis J. C. Jr., Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis and Rheumatism 2008 58 5 1324 1331 2-s2.0-43949140512 10.1002/art.23471 (Pubitemid 351705922)
25. Hyrich K. L., Lunt M., Watson K. D., Symmons D. P. M., Silman A. J., Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a Large UK National Cohort Study. Arthritis and Rheumatism 2007 56 1 13 20 2-s2.0-33846239331 10.1002/art.22331 (Pubitemid 46106174)
26. Arends S., Brouwer E., van der Veer E., Kallenberg C. G., Jansen T. L., Houtman P. M., Spoorenberg A., Effect of switching between infliximab, etanercept and adalimumab in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 2009 68 supplement 3 624
27. Cantini F., Niccoli L., Benucci M., Chindamo D., Nannini C., Olivieri I., Padula A., Salvarani C., Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Care and Research 2006 55 5 812 816 2-s2.0-33750318776 10.1002/art.22236 (Pubitemid 44619197)
28. Coates L. C., Cawkwell L. S., Ng N. W. F., Bennett A. N., Bryer D. J., Fraser A. D., Emery P., Marzo-Ortega H., Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Annals of the Rheumatic Diseases 2008 67 5 717 719 2-s2.0-42449160970 10.1136/ard.2007.082925 (Pubitemid 351571940)
29. Coates L. C., Cawkwell L. S., Ng N. W. F., Bennett A. N., Bryer D. J., Fraser A. D., Emery P., Marzo-Ortega H., Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology 2008 47 6 897 900 2-s2.0-44849086068 10.1093/rheumatology/ken094 (Pubitemid 351796381)
30. Conti F., Ceccarelli F., Marocchi E., Magrini L., Spinelli F. R., Spadaro A., Scrivo R., Valesini G., Switching tumour necrosis factor α antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Annals of the Rheumatic Diseases 2007 66 10 1393 1397 2-s2.0-34848860252 10.1136/ard.2007.073569 (Pubitemid 47492489)
31. Delaunay C., Farrenq V., Marini-Portugal A., Cohen J. D., Chevalier X., Claudepierre P., Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. Journal of Rheumatology 2005 32 11 2183 2185 2-s2.0-27744533609 (Pubitemid 41587865)
32. Pradeep D. J., Keat A. C., Gaffney K., Brooksby A., Leeder J., Harris C., Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology 2008 47 11 1726 1727 2-s2.0-54449099689 10.1093/rheumatology/ken334
33. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H., Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis and Rheumatism 2006 54 8 2665 2673 2-s2.0-33746951437 10.1002/art.21972 (Pubitemid 44205029)
34. van der Linden S., Valkenburg H. A., Cats A., Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and Rheumatism 1984 27 4 361 368 2-s2.0-0021272107 (Pubitemid 14134775)
35. Prevoo M. L. L., van Gestel A. M., van 'T Hof M. A., van Rijswijk M. H., van de Putte L. B. A., van Riel P. L. C. M., Remission in a prospective study of patients with rheumatoid arthritis. American rheumatism association preliminary remission criteria in relation to the disease activity score. British Journal of Rheumatology 1996 35 11 1101 1105 2-s2.0-0029906505
36. Gossec L., Smolen J. S., Gaujoux-Viala C., Ash Z., Marzo-Ortega H., van der Heijde D., FitzGerald O., Aletaha D., Balint P., Boumpas D., Braun J., Breedveld F. C., Burmester G., Cañete J. D., de Wit M., Dagfinrud H., de Vlam K., Dougados M., Helliwell P., Kavanaugh A., Kvien T. K., Landewé R., Luger T., Maccarone M., McGonagle D., McHugh N., McInnes I. B., Ritchlin C., Sieper J., Tak P. P., Valesini G., Vencovsky J., Winthrop K. L., Zink A., Emery P., European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Annals of the Rheumatic Diseases 2012 71 1 4 12 2-s2.0-82955236087 10.1136/annrheumdis-2011-200350
37. Garrett S., Jenkinson T., Kennedy L. G., Whitelock H., Gaisford P., Calin A., A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. Journal of Rheumatology 1994 21 12 2286 2291 2-s2.0-0028575453
38. Calin A., Garrett S., Whitelock H., O'Hea J., Mallorie P., Jenkinson T., A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. Journal of Rheumatology 1994 21 12 2281 2285 2-s2.0-0028579768
39. Jenkinson T. R., Mallorie P. A., Whitelock H. C., Kennedy L. G., Garrett S. L., Calin A., Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS metrology index. Journal of Rheumatology 1994 21 9 1694 1698 2-s2.0-0028129277 (Pubitemid 24285485)
40. Heuft-Dorenbosch L., Spoorenberg A., van Tubergen A., Landewé R., van der Tempel H., Mielants H., Dougados M., van der Heijde D., Assessment of enthesitis in ankylosing spondylitis. Annals of the Rheumatic Diseases 2003 62 2 127 132 2-s2.0-0037307863 10.1136/ard.62.2.127 (Pubitemid 36135387)
41. Fries J. F., The hierarchy of quality-of-life assessment, the Health Assessment Questionnaire (HAQ), and issues mandating development of a toxicity index. Controlled Clinical Trials 1991 12 supplement 4 106S 117S 2-s2.0-0025822870
42. Rudwaleit M., van der Heijde D., Landewé R., Akkoc N., Brandt J., Chou C. T., Dougados M., Huang F., Gu J., Kirazli Y., van den Bosch F., Olivieri I., Roussou E., Scarpato S., Sørensen I. J., Valle-Oñate R., Weber U., Wei J., Sieper J., The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Annals of the Rheumatic Diseases 2011 70 1 25 31 2-s2.0-78650679234 10.1136/ard.2010.133645
43. Rudwaleit M., Taylor W. J., Classification criteria for psoriatic arthritis and ankylosing spondylitis/axial spondyloarthritis. Best Practice and Research: Clinical Rheumatology 2010 24 5 589 604 2-s2.0-78049445173 10.1016/j.berh.2010.05.007
44. Scirè C. A., Caporali R., Sarzi-Puttini P., Frediani B., di Franco M., Tincani A., Sinigaglia L., Sfriso P., Tirri R., Bellis E., Delsante G., Porru G., Salaffi F., Giuggioli D., Rossini M., Todoerti M., Bazzichi L., Govoni M., Gerli R., Raschetti R., Minisola G., Montecucco C., Todesco S., Monitornet project. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. Clinical and Experimental Rheumatology 2013 31 857 863
45. Carmona L., Gómez-Reino J. J., Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Research and Therapy 2006 8 3, article R72 2-s2.0-34147219117 10.1186/ar1941
46. Lord P. A. C., Farragher T. M., Lunt M., Watson K. D., Symmons D. P. M., Hyrich K. L., Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2009 49 3 563 570 2-s2.0-77950525609 10.1093/ rheumatology/kep422 kep422
47. Kristensen L. E., Gülfe A., Saxne T., Geborek P., Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Annals of the Rheumatic Diseases 2008 67 3 364 369 2-s2.0-39549105616 10.1136/ard.2007.073544 (Pubitemid 351281272)
48. Saad A. A., Ashcroft D. M., Watson K. D., Hyrich K. L., Noyce P. R., Symmons D. P. M., Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Research and Therapy 2009 11 2, article R52 2-s2.0-65449189497 10.1186/ar2670
49. Hyrich K. L., Watson K. D., Silman A. J., Symmons D. P. M., Predictors of response to anti-TNF- α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006 45 12 1558 1565 2-s2.0-33751416149 10.1093/rheumatology/kel149 (Pubitemid 44817065)